Brokerages Set SI-BONE, Inc. (NASDAQ:SIBN) Price Target at $23.00

SI-BONE, Inc. (NASDAQ:SIBN) has been assigned a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $23.00.

SIBN has been the topic of several analyst reports. Truist Financial increased their target price on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a research report on Wednesday, November 20th.

SI-BONE Stock Performance

SIBN stock opened at $13.25 on Wednesday. SI-BONE has a twelve month low of $11.70 and a twelve month high of $21.70. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The company has a market cap of $555.68 million, a P/E ratio of -14.40 and a beta of 1.20. The business’s fifty day moving average is $13.42 and its 200-day moving average is $14.09.

Insider Activity

In other SI-BONE news, CFO Anshul Maheshwari sold 2,439 shares of SI-BONE stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $12.68, for a total value of $30,926.52. Following the sale, the chief financial officer now owns 194,623 shares of the company’s stock, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,937 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $12.60, for a total value of $49,606.20. Following the completion of the sale, the insider now owns 228,554 shares in the company, valued at approximately $2,879,780.40. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,679 shares of company stock worth $276,439 in the last 90 days. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On SI-BONE

A number of hedge funds and other institutional investors have recently bought and sold shares of SIBN. FMR LLC grew its stake in shares of SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in SI-BONE in the second quarter valued at $61,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in SI-BONE by 24.7% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,649 shares of the company’s stock valued at $138,000 after buying an additional 2,108 shares during the last quarter. Arizona State Retirement System lifted its position in SI-BONE by 9.0% during the 2nd quarter. Arizona State Retirement System now owns 10,921 shares of the company’s stock worth $141,000 after buying an additional 903 shares in the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of SI-BONE during the 3rd quarter worth about $144,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.